Formation Bio logo

TrialSpark, Inc.

Biotechnology

Formation Bio Stock

Formation Bio is a tech-driven, AI-native pharmaceutical company focused on revolutionizing drug development. By leveraging proprietary technology and a multidisciplinary team, the company accelerates the process of bringing treatments to patients, addressing unmet medical needs efficiently. Formation Bio acquires and develops clinical-stage assets, optimizing value and speed to market through innovative approaches.

Founded: 2016

Formation Bio Website

For more Formation Bio stock information, or to buy or sell private shares, sign up for a MicroVentures account.

Formation Bio Company Overview

Founded with the mission to transform the pharmaceutical industry, Formation Bio integrates advanced technology and artificial intelligence into the drug development process. The company focuses on addressing the inefficiencies that have traditionally slowed down the journey from drug discovery to patient treatment. By acquiring clinical-stage drugs from pharmaceutical companies, universities, and biotech firms, Formation Bio aims to bring potential treatments to market more rapidly and cost-effectively. Formation Bio's proprietary platform combines cutting-edge technology with a rigorous approach to process improvement, allowing for faster development cycles without compromising safety and quality. This approach is underpinned by a team of experts who have collectively contributed to over 45 approved drugs, drawing from deep expertise in drug selection, development, and software technology. The company’s model emphasizes early value realization in drug programs, providing partners with accelerated access to treatment milestones that are crucial in the industry. By addressing the bottlenecks that have traditionally plagued drug development, Formation Bio is poised to meet critical unmet patient needs across various therapeutic areas, positioning itself as a leader in the future of pharmaceutical innovation.

Management Team

Ben Liu Co-Founder, CEO
Linhao Zhang Co-Founder, CTO
Gavin Corcoran CDO
James Leslie CFO
Melissa Enbar Chief People Officer

Funding Information